Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
FAIL · Does not pass the screen
27.91 USD
At the last full screen 2026-09-01
Screened 2026-09-01 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Xencor, Inc. holds its Markup at $27.91. Consolidating, no directional conviction, held for 5 days.
As held on the ledger · 2026-09-01
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 5 days
Price at the screen
$27.91
Valuation
N/A trailing · -7.97 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.84
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
21.44%
Below 33%
Interest-bearing debt is just 21.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.06%
Below 33%
Cash held in interest-bearing accounts and securities is 20.1% of assets, under the one-third limit.
Pass
Receivables
9.52%
Below 49%
Money owed to the company is 9.5% of assets, under the 49% limit.
Pass
Revenue purity
21.92%
Below 5%
21.9% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-01 screen. The gold marker is the market price at the same screen. A 2.1% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus None. The average target sits +2% from the screen price.
Reading the gap · Our model and the Street both land near today's price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech With Shrinking Sales And Heavy Losses
Picture a lab racing to turn antibody ideas into approved drugs while sales keep sliding off a cliff. Xencor is exactly that story, a clinical stage player chasing cancer and autoimmune treatments with revenue already down 86 percent and margins at minus 177 percent. The numbers show a company burning cash fast and posting a negative 30 percent return on equity, so we pass despite the clean ethical screen and analyst enthusiasm.
The forward multiple sits at minus 4.9 times, which simply reflects deepening losses rather than any bargain. A 55 percent gap to the $27 median target looks tempting on paper, yet the underlying business shows no clear path to sustained profits or a durable moat. Strong buy ratings from twelve analysts do not change the weak operating reality.
Risk sits in the usual clinical stage traps of trial failures and dilution, made worse by the sharp revenue drop. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
XNCR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-18Markup · changed$22.99+86.5%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 86.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (12 analysts) rates it none, with a mean price target of $28.
2026-07-18Distribution$12.33+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (12 analysts) rates it none, with a mean price target of $28.
2026-07-03Distribution$12.33+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$12.33Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.